Injectable treatment for knee OA launched across Pure Sports Medicine network

Contura Orthopaedics has announced that Arthrosamid®, a non-biodegradable hydrogel injectable implant for knee osteoarthritis (OA), is now available at Pure Sports Medicine clinics in London and the South East.

Pure Sports Medicine, a leading provider of musculoskeletal and sports medicine, will offer Arthrosamid® to patients seeking non-surgical solutions for OA-related pain and discomfort. The treatment, which involves a single 6ml injection into the knee joint, has been shown to provide long-lasting pain relief and can provide an effective alternative to invasive knee replacement surgery for suitable patients.

Dr John Etherington CBE, consultant rheumatologist and medical director at Pure Sports Medicine, said: ‘With so little known about the exact causes of knee OA, many people find themselves in an ongoing cycle of treatments, such as painkillers or knee joint injectables (e.g. steroids or hyaluronic acid). Despite providing some relief, the effects can often be relatively short-lived, leaving many fearing that knee replacement surgery is the only long-term answer. But with lengthy recovery times and the risk of repeat surgical procedures needed further down the line, this is often not the best choice for younger, active patients with significant pain and early osteoarthritis.’

Clinical data supports the efficacy of Arthrosamid®, with recent four-year results presented at the European Orthopaedic Research Society Meeting in September 2024 demonstrating significant pain reduction maintained over the long term. The treatment is aimed at patients who have not responded to other therapies, those too young for surgery, or individuals unable to take time off work for major procedures.

Rakesh Tailor, CEO at Contura International, said: ‘We’re thrilled to be working so collaboratively with the progressive team at Pure Sports Medicine in a new partnership that will really help to improve awareness and widen access to Arthrosamid®. There has been a lack of innovation and so the treatment options for the thousands of people affected by the debilitating pain caused by knee OA are limited.’

The announcement comes as part of a broader rollout of Arthrosamid®, which has been used in over 13,000 procedures across Europe over the last three years.